Showing posts with label corticotrophin-releasing factor receptor 1. Show all posts
Showing posts with label corticotrophin-releasing factor receptor 1. Show all posts

Tuesday, March 03, 2015

The Roots of Anxiety Induced Pain

Corticotropin-Releasing Factor and ERK1/2 Pathway

This study crossed my radar scope because the investigators referenced use of our phosphoERK1/2 for Western Blotting and Immunohistochemistry: Gisela Patrícia da Silva Borges , Juan Antonio Micó Segura , Fani Lourença Moreira Neto , Esther Berrocoso. Corticotropin-Releasing Factor Mediates Pain-Induced Anxiety through the ERK1/2 Signaling Cascade in Locus Coeruleus Neurons. DOI: http://dx.doi.org/10.1093/ijnp/pyv019 First published online: 25 February 2015

Conclusion: pain-induced anxiety is mediated by CRF neurotransmission in the LC through ERK1/2 signaling cascade.

Figure: a) Schematic representation of the anatomical pathways implicated. Briefly, the contralateral LC indirectly receives inputs from the inflamed paw (red dashed line; ascending pathways) and, subsequently, the information is sent to corticolimbic areas. Additionally, the LC sends direct projections to the spinal cord (blue straight line; descending pathways). b) Body weight of the control and MA rats. c) Body rectal temperature of control and MA rats. d) Mechanical hyperalgesia represented by a significant decrease in the paw withdrawal threshold of the ipsilateral paw of MA rats. e) Mechanical allodynia represented by a significant decrease in the force threshold of the ipsilateral paw of MA rats. Graph depicting the expression of pERK1/2 in the LC after intra-LC administration of the αCRF receptor antagonist, showing that the significant increase of pERK1/2 in MA4W animals was no longer observed when this antagonist was administered.  g) Graph showing that the local administration of the αCRF antagonist had no significant effect on mechanical hyperalgesia in MA4W rats. h) Graph showing that local administration of h) Graph showing that local administration of the α-helical CRF antagonist had no significant effect on mechanical allodynia in the ipsilateral paw of MA rats. i) Graph showing that the time spent in the open arms decreased in MA4W rats receiving the vehicle alone but this effect was successfully reversed by administration of the αCRF antagonist. j) Graph showing that local administration of the α-helical CRF antagonist had no significant effect on the total distance traveled in the elevated zero maze. k) Graph showing that local administration of the α-helical CRF antagonist reversed the decrease in the number of entries into the open arms observed in MA4W rats receiving the vehicle alone. B=Baseline; LC=Locus Coeruleus; αCRF=antagonist of the corticotropin-releasing factor receptor I and II; W=Week; MA=Monoarthritis.
 

Western Blotting: The membranes were blocked with 5% Bovine Serum Albumin (BSA; Sigma, Spain) in TBST and probed overnight at 4 ºC with a rabbit anti-phospho-ERK1/2 (1:5,000; Neuromics). Immunohistochemistry: Brains were removed and processed for free-floating immunohistochemistry. One in five sequential transverse brain sections (30 µm) containing the PVN from each rat were washed, blocked and incubated with a rabbit antiserum against the phosphorylated ERK1 and ERK2 isoforms (pERK1/2; 1:1000; 48 hours at 4-8ºC: Neuromics, USA). Immunodetection was achieved with a biotinylated donkey anti-rabbit antiserum (1:500; 1 hour; Jackson ImmunoResearch, USA), followed by an ABC solution (1:200, 1 hour; ABC Elite kit, Vector Laboratories, UK) and a colorimetric reaction with 3,3-diaminobenzidine tetrahydrochloride (DAB; 10 min) in 0.05M Tris-HCl buffer containing 0.003% hydrogen peroxide (Cruz et al., 2005). Sections were then washed in PBS, mounted on gelatin-coated glass slides, cleared in xylene, cover-slipped with DPX and analyzed by light microscopy.

We have a broad range of pain and inflammatory response research markers. Check us out today.


Tuesday, April 20, 2010

CFR1, 5-HT2AR and Anxiety Behavior

We have a potent offering of 5HT-Serotonin Antibodies. This is confirmed by our growing parade of customer publications referencing their use.

We are pleased to present a new publication referencing use of our 5HT (Serotonin) 2A Receptor Antibody. Dr. Stephen S G Ferguson and team have discovered a link between CFR1 and 5-HT2A Receptor expression:

Ana C Magalhaes,Kevin D Holmes,Lianne B Dale,Laetitia Comps-Agrar,Dennis Lee,Prem N Yadav, Linsay Drysdale, Michael O Poulter, Bryan L Roth, Jean-Philippe Pin, Hymie Anisman& Stephen S G Ferguson. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nature Neuroscience. doi:10.1038/nn.2529. Published online11 April 2010.


Abstract: Stress and anxiety disorders are risk factors for depression and these behaviors are modulated by corticotrophin-releasing factor receptor 1 (CRFR1) and serotonin receptor (5-HT2R). However, the potential behavioral and cellular interaction between these two receptors is unclear. We found that pre-administration of corticotrophin-releasing factor (CRF) into the prefrontal cortex of mice enhanced 5-HT2R–mediated anxiety behaviors in response to 2,5-dimethoxy-4-iodoamphetamine. In both heterologous cell cultures and mouse cortical neurons, activation of CRFR1 also enhanced 5-HT2 receptor–mediated inositol phosphate formation. CRFR1-mediated increases in 5-HT2R signaling were dependent on receptor internalization and receptor recycling via rapid recycling endosomes, resulting in increased expression of 5-HT2R on the cell surface. Sensitization of 5-HT2R signaling by CRFR1 required intact PDZ domain–binding motifs at the end of the C-terminal tails of both receptor types. These data suggest a mechanism by which CRF, a peptide known to be released by stress, enhances anxiety-related behavior via sensitization of 5-HT2R signaling.

Images: (a) Dose response curves for 5-HT–stimulated inositol phosphate formation in HEK 293 cells transfected with FLAG–5-HT2AR and HA-CRFR1 and pretreated with or without 500 nM CRF for 30 min in the presence of dominant-negative dynamin I-K44A. The dose response curves represent the mean ± s.e.m. for four independent experiments. (b,c) Representative laser-scanning confocal micrographs showing the distribution of FLAG-5-HT2AR and HA-CRFR1 (b) and FLAG-5-HT2CR and HA-CRFR1 (c) in HEK 293 cells labeled with FLAG and HA antibodies at 4 °C and then warmed to 37 °C for 30 min in the absence of agonist. (d) Representative laser-scanning confocal micrographs showing the distribution of FLAG–5-HT2AR and HA-CRFR1 labeled with FLAG and HA antibodies at 4 °C and warmed to 37 °C for 30 min in the absence of agonist. (e) Representative laser-scanning confocal micrographs showing the distribution of FLAG–5-HT2AR and HA-CRFR1 transfected into rat cortical neurons labeled with FLAG and HA antibodies at 4 °C and treated with 500 nM CRF and warmed to 37 °C for 30 min. (f) Representative laser-scanning confocal micrographs showing the distribution of FLAG–5-HT2AR and HA-β2AR transfected into HEK 293 cells labeled with FLAG and HA antibodies at 4 °C and treated with 100 μM isoproterenol and warmed to 37 °C for 30 min. Micrographs are representative images of multiple cells imaged on three independent occasions. Scale bars represent 10 μm.

Related Reagents:
All 5HT-Serotonin Antibodies

Neurotransmission Research Antiboodies

Primary Neurons and Astrocytes

-Primary human, rat and mouse neurons and astrocytes